Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease

Biol Pharm Bull. 2013;36(1):140-3. doi: 10.1248/bpb.b12-00798. Epub 2012 Oct 16.

Abstract

We previously reported the protective effects of long-term administration of ferulic acid against the in vivo toxicity of β-amyloid peptide administered intracerebroventricularly in mice. In the present study, we investigated the effects of ferulic acid in transgenic amyloid precursor protein (APP)swe/presenilin 1 (PS1)dE9 (APP/PS1) mouse model of Alzheimer disease (AD). Chronic (for 6 months from the age of 6 to 12 months) oral administration of ferulic acid at a dose of 5.3 mg/kg/day significantly enhanced the performance in novel-object recognition task, and reduced amyloid deposition and interleukin-1 beta (IL-1β) levels in the frontal cortex. These results suggest that ferulic acid at a certain dosage could be useful for prevention and treatment of AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / metabolism
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • Behavior, Animal / drug effects
  • Coumaric Acids / therapeutic use*
  • Female
  • Frontal Lobe / drug effects
  • Frontal Lobe / metabolism
  • Interleukin-1beta / metabolism
  • Mice
  • Mice, Transgenic
  • Neuroprotective Agents / therapeutic use*
  • Presenilin-1 / genetics
  • Recognition, Psychology / drug effects

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Coumaric Acids
  • Interleukin-1beta
  • Neuroprotective Agents
  • Presenilin-1
  • ferulic acid